# US 2023/0264044 A1 · Convection-Enhanced Diffusing Alpha-Emitter Radiation Therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0264044 A1
- Document ID: US20230264044A1
- Status: Published application
- Kind: A1
- Application number: 18/113,097
- Filed: 2023-02-23
- Published: 2023-08-24
- Earliest claimed: 2022-02-24
- Assignees: Alpha Tau Medical Ltd.
- Applicants: Alpha Tau Medical Ltd.
- Inventors: Lior Arazi; Itzhak Kelson; Ronen Segal; Raphael Aryeh Levy
- Web page: https://patentgrep.com/patent/US20230264044A1

## CPC

- A61N 5/1007: {Arrangements or means for the introduction of sources into the body}
- A61N 5/1027: {Interstitial radiation therapy}
- A61N 2005/1021: {Radioactive fluid}
- A61N 2005/1087: {Ions; Protons}
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

A device for treating a tumor, including a needle for insertion into the tumor, a solution generator configured to generate a liquid solution including free radionuclides at a concentration of at least 1*106 atoms per microliter, and a pump which continuously pumps the generated solution into the needle.

## Claims

### Claim 1

A method of treating a tumor, comprising:
identifying a tumor; and
injecting a liquid including free radionuclides into the tumor, for a duration of at least 6 hours.

### Claim 2 (depends on 1)

The method of claim 1, wherein identifying the tumor comprises identifying a tumor having a largest diameter of at least 2 centimeters and wherein injecting the liquid comprises injecting through a single needle.

### Claim 3 (depends on 1)

The method of claim 1, wherein injecting the liquid comprises injecting for a duration of at least 72 hours.

### Claim 4 (depends on 3)

The method of claim 3, wherein injecting the liquid comprises injecting for a duration of at least 110 hours.

### Claim 5 (depends on 1)

The method of claim 1, wherein injecting the liquid comprises injecting a liquid including beta-emitting radionuclides.

### Claim 6 (depends on 1)

The method of claim 1, wherein injecting the liquid comprises injecting a liquid including alpha-emission-treatment radionuclides.

### Claim 7 (depends on 6)

The method of claim 6, wherein injecting the liquid comprises injecting a liquid including 212Pb radionuclides.

### Claim 8 (depends on 1)

The method of claim 1, wherein injecting the liquid comprises injecting a liquid including at least 2*107 radionuclides of an alpha-emission-treatment isotope per microliter.

### Claim 9 (depends on 1)

The method of claim 1, wherein injecting the liquid comprises injecting a liquid which does not include more than negligible amounts of 224Ra, 220Rn, and 216Po.

### Claim 10 (depends on 1)

The method of claim 1, wherein injecting the liquid comprises injecting at a rate of at least 2.5 microliters per minute.

### Claim 11 (depends on 1)

The method of claim 1, wherein injecting the liquid comprises injecting at a rate of not more than 10 microliters per minute.

### Claim 12 (depends on 1)

The method of claim 1, wherein injecting the liquid comprises pumping a liquid through a vial holding therein one or more seeds with parent radionuclides attached to the seeds in a manner that the parent radionuclides do not leave the seed, but a substantial percentage of daughter nuclides leave the seeds into the liquid, upon decay.

### Claim 13 (depends on 12)

The method of claim 12, wherein the one or more seeds carry at least 10 microcurie of 224Ra radionuclides.

### Claim 14 (depends on 13)

The method of claim 13, wherein the one or more seeds carry at least 100 microcurie of 224Ra radionuclides.

### Claim 15 (depends on 14)

The method of claim 14, wherein the one or more seeds carry at least 250 microcurie of 224Ra radionuclides.

### Claim 16 (depends on 1)

The method of claim 1, further comprising:
acquiring an image of the dispersion of the radionuclides in the tumor;
determining whether an area of the tumor is not receiving a sufficient number of radionuclides responsive to the acquired image; and
adjusting a parameter of the injecting responsive to determining that an area of the tumor is not receiving a sufficient number of radionuclides.

### Claim 17 (depends on 16)

The method of claim 16, wherein at least some of the radionuclides are injected coupled to nanoparticles which serve as contrast agents which appear in the acquired image.

### Claim 18 (depends on 16)

The method of claim 16, wherein adjusting the parameter comprises changing a flow rate of injecting the liquid.

### Claim 19 (depends on 16)

The method of claim 16, wherein adjusting the parameter comprises changing a concentration of the radionuclides in the liquid.

### Claim 20

A device for treating a tumor, comprising:
a needle for insertion into the tumor;
a solution generator configured to generate a liquid solution including free alpha-emission-treatment radionuclides at a concentration of at least 1*106 atoms per microliter; and
a pump which continuously pumps the generated solution into the needle.

### Claim 21 (depends on 20)

The device of claim 20, further comprising a controller which is programmed to control the pump to pump the liquid solution through the vial into the needle continuously for at least 24 hours.

### Claim 22 (depends on 21)

The device of claim 21, wherein the controller is programmed to control the pump to pump the liquid solution through the vial at a rate of at least 2.5 microliters per minute.

### Claim 23 (depends on 21)

The device of claim 21, wherein the controller is programmed to control the pump to pump the liquid solution through the vial at a rate of at least 10 microliters per minute.

### Claim 24 (depends on 20)

The device of claim 20, wherein the solution generator is configured to generate the liquid solution with 212Pb radionuclides at a concentration of at least 2*109 atoms per microliter.

### Claim 25 (depends on 20)

The device of claim 20, wherein the solution generator comprises:
a vial including therein one or more seeds with radium radionuclides attached to the seeds in a manner that the radium radionuclides do not leave the seed, but a substantial percentage of daughter radionuclides leave the seeds upon decay; and
a tube connecting the vial to the needle,
wherein the pump is configured to pump a liquid through the vial, into the tube, so as to generate the solution.

### Claim 26 (depends on 25)

The device of claim 25, wherein the one or more seeds carry at least 10 microcurie of 224Ra radionuclides.

### Claim 27 (depends on 26)

The device of claim 26, wherein the one or more seeds carry at least 100 microcurie of 224Ra radionuclides.

### Claim 28 (depends on 27)

The device of claim 27, wherein the one or more seeds carry at least 250 microcurie of 224Ra radionuclides.

### Claim 29 (depends on 20)

The device of claim 20, wherein the solution generator is configured to generate a liquid solution including 212Pb atoms at a concentration of at least 1*108 atoms per microliter.

### Claim 30

A solution for treating a tumor, comprising:
a bio-compatible liquid solution including free 212Pb atoms at a concentration of between 1*106 and 1*1011 atoms per microliter.

### Claim 31 (depends on 30)

The solution of claim 30, wherein the solution includes 212Pb atoms at a concentration of at least 1*107 atoms per microliter.

### Claim 32 (depends on 30)

The solution of claim 30, wherein the solution includes 212Pb atoms at a concentration of at least 1*108 atoms per microliter.

### Claim 33 (depends on 32)

The solution of claim 32, wherein the solution includes 212Pb atoms at a concentration of less than 2*109 atoms per microliter.

### Claim 34 (depends on 30)

The solution of claim 30, wherein the solution includes 212Pb atoms at a concentration of at least 1*109 atoms per microliter.

### Claim 35 (depends on 30)

The solution of claim 30, wherein the solution is suitable for convection-enhanced delivery of the 212Pb atoms.
